Boosting Ebola Preparedness with Diversified Vaccine Technologies

🦟 𝐃𝐞𝐧𝐠𝐮𝐞 𝐕𝐚𝐜𝐜𝐢𝐧𝐞 𝐌𝐚𝐫𝐤𝐞𝐭 𝐆𝐚𝐢𝐧𝐢𝐧𝐠 𝐌𝐨𝐦𝐞𝐧𝐭𝐮𝐦 𝐢𝐧 𝐆𝐥𝐨𝐛𝐚𝐥 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐆𝐞𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅 𝐰𝐢𝐭𝐡 𝐚𝐥𝐥 𝐆𝐫𝐚𝐩𝐡𝐬 & 𝐂𝐡𝐚𝐫𝐭𝐬✅Access Free Sample Copy of Dengue Vaccine Market Report @ https://lnkd.in/d6heZstw The “Dengue Vaccine Market” is expanding rapidly as governments, healthcare organizations, and pharmaceutical companies intensify efforts to combat rising dengue infections worldwide. 📊 Increasing awareness about mosquito-borne diseases, growing immunization programs, and advancements in vaccine research are driving significant investments in dengue prevention technologies. 💉 From live attenuated vaccines to next-generation biotechnology platforms, innovation is reshaping the future of infectious disease management and public health preparedness. 🌍 Rising cases across tropical and subtropical regions are accelerating demand for effective dengue vaccines, strengthening collaborations between biotech firms, research institutes, and global healthcare agencies. ⚙️ AI-driven research, advanced clinical trials, and precision vaccine development are helping companies improve efficacy, safety, and large-scale vaccine distribution strategies worldwide. #DengueVaccine #Healthcare #Biotechnology #Vaccines #Pharma #AI #PublicHealth #LifeSciences #Immunization #HealthcareInnovation #Biotech #MedicalResearch 𝐋𝐞𝐚𝐝𝐢𝐧𝐠 𝐨𝐫𝐠𝐚𝐧𝐢𝐳𝐚𝐭𝐢𝐨𝐧𝐬 𝐚𝐜𝐭𝐢𝐯𝐞 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐦𝐚𝐫𝐤𝐞𝐭 𝐢𝐧𝐜𝐥𝐮𝐝𝐞 – Gavi, the Vaccine Alliance International Vaccine Institute (IVI) Vaccine Valley The Duke Human Vaccine Institute Center for Vaccine Development & Global Health Oxford Vaccine Group Razi Vaccine & Serum Research Institute Seattle Vaccine Trials Unit Vaccine World Forum Incepta Vaccine Ltd Vaccine Fairy Centre for Vaccine Research and Biotechnology SSID Group - Disease surveillance & Vaccine development The World Vaccine Congress 2023 VACCINE TECHNOLOGY LIMITED Vaccine Development AI UK Clinical Vaccine Network Australian Vaccine Services Pty Ltd Incepta Pharmaceuticals Ltd. (Vaccine Division) Saint Louis University, Center for Vaccine Devleopment IT Services and IT Consulting Pharmaceutical Manufacturing Infollion Research Services Limited Pharmaceutical Manufacturing Biotechnology Research The Jordanian Pharmaceutical Manufacturing Company Pharmaceutical Manufacturing Pharmaceutical Manufacturing Technology Centre Pharmaceutical Manufacturing Bepex LTD-Pharmaceutical AND Manufacturing Vaccine Advisor COVID-19 Vaccine Information Distribution Student Task Force - UMD The Duke Human Vaccine Institute Vaccine Injury Lawyers We Are Striving For Vaccine Adith a Vaccine Pharma We Are Striving For Vaccine

Next-Generation Vaccines for Emerging Viruses: Insights from a Hantavirus Study: Recent concerns regarding emerging and re-emerging viral outbreaks, including hantavirus infections in different regions of the world, continue to emphasize the urgent need for effective vaccines and antiviral therapeutics. With increasing human exposure to rodent reservoirs and the ongoing risk of zoonotic spillover events, strengthening pandemic preparedness through vaccine innovation and translational virology research remains critically important for future public health protection. In this context, a new study published in Nature Communications reports a prefusion-stabilized nucleic acid vaccine targeting . The vaccine induced potent neutralizing antibody responses and strong germinal center activation, highlighting the generation of high-quality and potentially durable humoral immunity. The work underscores the value of structure-based antigen design, where stabilizing viral glycoproteins in their prefusion conformation can markedly enhance vaccine immunogenicity. This strategy, already validated in other viral systems such as RSV and SARS-CoV-2, is now being extended to hantaviruses, expanding its relevance across emerging infectious diseases. Overall, studies like this are not only important for addressing current hantavirus-related risks but also provide a framework for preparedness against future viral outbreaks by advancing next-generation vaccine platforms and immunogen design strategies. #Virology #Vaccines #Immunology #Hantavirus #NatureCommunications #EmergingViruses #InfectiousDiseases #StructuralBiology #PandemicPreparedness s41467-026-70285-7_reference.pdf https://lnkd.in/eiN6kzpp

PSI researchers have recently discussed their ongoing work on Bundibugyo Ebola vaccines and treatments at a Science Media Centre briefing and with several UK and global outlets.   Read a selection of the coverage. https://lnkd.in/dwdCFKS4

𝐖𝐨𝐫𝐥𝐝 𝐈𝐦𝐦𝐮𝐧𝐢𝐳𝐚𝐭𝐢𝐨𝐧 𝐖𝐞𝐞𝐤 (𝟐𝟒 - 𝟑𝟎 𝐀𝐩𝐫𝐢𝐥 𝟐𝟎𝟐𝟔) Strong vaccines need strong immune responses. Based at IBG, the 𝐍𝐇𝐌𝐑𝐂 𝐂𝐞𝐧𝐭𝐫𝐞 𝐨𝐟 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐄𝐱𝐜𝐞𝐥𝐥𝐞𝐧𝐜𝐞 𝐢𝐧 𝐕𝐚𝐜𝐜𝐢𝐧𝐞 𝐀𝐝𝐣𝐮𝐯𝐚𝐧𝐭 𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲 & 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 (𝐕𝐚𝐜𝐜𝐢𝐧𝐞‑𝐀𝐃𝐃), advancing new adjuvants that improve the strength and durability of vaccine‑induced immunity. This work underpins the next generation of safer, more effective vaccines. Respiratory bacterial infections remain a major global health challenge. 𝐃𝐫 𝐉𝐨𝐡𝐧 𝐀𝐭𝐚𝐜𝐤 and colleagues at IBG are developing a 𝐮𝐧𝐢𝐯𝐞𝐫𝐬𝐚𝐥 𝐯𝐚𝐜𝐜𝐢𝐧𝐞 𝐚𝐩𝐩𝐫𝐨𝐚𝐜𝐡 𝐭𝐚𝐫𝐠𝐞𝐭𝐢𝐧𝐠 𝐧𝐨𝐧‑𝐭𝐲𝐩𝐞𝐚𝐛𝐥𝐞 𝗛𝗮𝗲𝗺𝗼𝗽𝗵𝗶𝗹𝘂𝘀 𝗶𝗻𝗳𝗹𝘂𝗲𝗻𝘇𝗮𝗲 —a leading cause of respiratory disease across all ages. The goal: broader, longer‑lasting protection against a major unmet medical need. IBG researchers, 𝐀/𝐏𝐫𝐨𝐟 Manisha Pandey 𝐚𝐧𝐝 𝐄𝐦. 𝐏𝐫𝐨𝐟 𝐌𝐢𝐜𝐡𝐚𝐞𝐥 𝐆𝐨𝐨𝐝 𝐀𝐎 are advancing 𝐯𝐚𝐜𝐜𝐢𝐧𝐞 𝐝𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲 𝐩𝐫𝐨𝐠𝐫𝐚𝐦𝐬 𝐭𝐚𝐫𝐠𝐞𝐭𝐢𝐧𝐠 𝐒𝐭𝐫𝐞𝐩𝐭𝐨𝐜𝐨𝐜𝐜𝐮𝐬 𝐀 (𝐒𝐭𝐫𝐞𝐩 𝐀)—a pathogen responsible for significant global disease burden, particularly in vulnerable populations and children. Malaria remains one of the world’s deadliest infectious diseases. 𝐓𝐰𝐨 𝐈𝐁𝐆 𝐭𝐞𝐚𝐦𝐬 𝐥𝐞𝐝 𝐛𝐲 𝐀/𝐏𝐫𝐨𝐟 Danielle Stanisic 𝐰𝐢𝐭𝐡 𝐄𝐦. 𝐏𝐫𝐨𝐟 𝐌𝐢𝐜𝐡𝐚𝐞𝐥 𝐆𝐨𝐨𝐝 𝐀𝐎, 𝐚𝐧𝐝 𝐏𝐫𝐨𝐟 Bernd Rehm are progressing separate 𝐦𝐚𝐥𝐚𝐫𝐢𝐚 𝐯𝐚𝐜𝐜𝐢𝐧𝐞 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐩𝐫𝐨𝐠𝐫𝐚𝐦𝐬, working across immunology, parasitology and nanotechnology and engaging with industry partners to support translation from discovery toward impact. 𝐏𝐫𝐨𝐟 𝐌𝐢𝐜𝐡𝐚𝐞𝐥 𝐉𝐞𝐧𝐧𝐢𝐧𝐠𝐬 𝐚𝐧𝐝 𝐏𝐫𝐨𝐟 Kate Seib have partnered with a European biopharma to develop a 𝐠𝐨𝐧𝐨𝐜𝐨𝐜𝐜𝐚𝐥 𝐯𝐚𝐜𝐜𝐢𝐧𝐞 𝐜𝐚𝐧𝐝𝐢𝐝𝐚𝐭𝐞 𝐢𝐧𝐯𝐞𝐧𝐭𝐞𝐝 𝐚𝐭 𝐈𝐁𝐆, aimed at tackling the global rise in gonorrhoea and antimicrobial resistance.

A strong highlight of ongoing vaccine research focused on improving protection, precision, and public health impact 👏🧬 Advances in modern vaccine platforms—including mRNA-based and targeted immunological approaches—are helping scientists develop more effective and adaptable vaccines for infectious diseases and beyond 🌍 (turn0search3 ) These innovations are part of a broader global push to strengthen prevention, reduce disease burden, and improve healthcare resilience through science-driven solutions. As research like this continues to evolve, https://lnkd.in/gqUUfhTU connects academics, researchers, and healthcare professionals with global opportunities in higher education—supporting impactful scientific work worldwide. #AcademicJobs #HigherEd #ResearchInnovation

𝗩𝗮𝗰𝗰𝗶𝗻𝗲 𝘀𝗰𝗶𝗲𝗻𝗰𝗲 𝗳𝗲𝗲𝗹𝘀 𝗱𝗶𝗳𝗳𝗲𝗿𝗲𝗻𝘁 𝘁𝗵𝗶𝘀 𝘆𝗲𝗮𝗿 Over the past few weeks: • Reports of a hantavirus outbreak linked to a cruise ship have made global headlines • Moderna published Phase 3 data showing its mRNA influenza vaccine outperformed standard flu vaccines in adults over 50 Two very different stories But together they highlight something important 𝗜𝗻𝗳𝗲𝗰𝘁𝗶𝗼𝘂𝘀 𝗱𝗶𝘀𝗲𝗮𝘀𝗲 𝘁𝗵𝗿𝗲𝗮𝘁𝘀 𝗮𝗿𝗲 𝗻𝗼𝘁 𝘀𝗹𝗼𝘄𝗶𝗻𝗴 𝗱𝗼𝘄𝗻 And our vaccine technologies cannot stay static either For decades, seasonal influenza vaccines have relied on traditional manufacturing approaches that are effective but relatively slow to adapt and optimize The new Phase 3 data for Moderna’s mRNA-1010 vaccine is interesting not just because it met superiority endpoints But because it reinforces what mRNA platforms may fundamentally change: Speed of design Strain adaptability Precision antigen engineering Rapid manufacturing scalability In the study involving more than 40,000 adults over age 50, mRNA-1010 showed a relative vaccine efficacy of 26.6% over standard-dose licensed influenza vaccines. That is a meaningful signal for the field of respiratory vaccines 𝗕𝘂𝘁 𝘁𝗵𝗲𝗿𝗲 𝗶𝘀 𝗮𝗻𝗼𝘁𝗵𝗲𝗿 𝘀𝗶𝗱𝗲 𝘁𝗼 𝘁𝗵𝗶𝘀 The study also reported higher reactogenicity, including fatigue, headache, myalgia, and injection-site pain compared with standard flu vaccines. And this is where the field still needs to evolve Delivery systems LNP composition Innate immune activation Antigen expression kinetics Dose optimization These will likely define the next generation of mRNA vaccines as much as the RNA itself 𝗧𝗵𝗮𝘁 𝗶𝘀 𝘄𝗵𝘆 𝘁𝗵𝗶𝘀 𝗺𝗼𝗺𝗲𝗻𝘁 𝗶𝘀 𝘀𝗼 𝗶𝗻𝘁𝗲𝗿𝗲𝘀𝘁𝗶𝗻𝗴 While the world is reacting to emerging outbreaks like hantavirus, vaccine science is simultaneously undergoing one of its biggest technological shifts in decades. The future may not belong to a single platform It may belong to platforms that can adapt fastest while balancing efficacy, safety, manufacturability, and global deployment And we are only beginning to see what that looks like. #Vaccines #mRNA #Influenza #Biotech #Immunology #DrugDevelopment #InfectiousDisease https://lnkd.in/ezbfHhtG https://lnkd.in/ezVFGrtr

The FMD vaccine immunogenicity puzzle 🧬 Building an FMD vaccine? You're solving one of virology's toughest problems: The challenge: FMD virus has extremely high mutation rates (10⁻³ to 10⁻⁴ errors/nucleotide). A vaccine that protects against serotype O in Year 1 may have reduced efficacy in Year 3 as field strains drift. Current industry approach: • Inactivated whole virus (traditional): 90-95% seroconversion, but requires high antigen loading & cold chain • Subunit/VLP vaccines: Better stability, but 70-85% seroconversion—often requires boosters • DNA/mRNA candidates: Faster manufacturing, but still in Phase 2/3 trials The bottleneck: Vaccine potency (ELISA units per dose) doesn't always correlate with field efficacy. A vaccine may show >90% seroconversion in controlled trials but only 75% protection in endemic regions with mixed serotypes. What the industry is solving right now: ✓ Chimeric antigen designs (combining multiple epitopes from circulating strains) ✓ Adjuvant optimization for mucosal immunity enhancement ✓ Real-time strain surveillance → rapid vaccine reformulation protocols The winning vaccines aren't just immunogenic—they're adaptable. The companies building dynamic vaccine platforms (not one-shot formulations) will dominate next decade. #FMDVaccine #VaccineR&D #Immunology #Virology #Biotechnology

Cervical Cancer Vaccines Market Gains Momentum as Prevention Becomes a Global Priority The Cervical Cancer Vaccines Market is projected to grow from US$ 10.3 billion in 2026 to US$ 16.4 billion by 2033, registering a CAGR of 6.8%. Rising awareness of HPV-related cervical cancer, stronger immunization programs, and growing investment in women’s preventive healthcare are supporting steady market expansion worldwide. Get Free Research PDF from Here- https://lnkd.in/dc3qKPkw 🔍 What’s Driving This Growth? • Increasing focus on HPV vaccination and cervical cancer prevention • Expanding government-led immunization programs • Rising awareness among adolescents, women, parents, and healthcare providers • Improved vaccine availability across emerging healthcare markets • Growing emphasis on early prevention rather than late-stage treatment 🔋 Why This Market Attracts Investment: • Strong demand for preventive oncology solutions • Expanding public health funding and vaccination coverage • Rising opportunities across Asia Pacific and other developing regions • Growing role of pharmaceutical companies in vaccine innovation • Long-term market potential driven by women’s health initiatives 🏢 Companies Covered in Cervical Cancer Vaccines Market: • Merck & Co., Inc. • GlaxoSmithKline plc • Serum Institute of India Pvt. Ltd. • Walvax Biotechnology Co., Ltd. • Beijing Wantai BioPharm • Shanghai Zerun Biotechnology • Xiamen Innovax Biotech • Sanofi • Pfizer Inc. • INOVIO Pharmaceuticals • Astellas Pharma • Emergent BioSolutions 💡 Key Takeaway: The Cervical Cancer Vaccines Market is becoming an important part of global preventive healthcare. With stronger vaccination programs, rising awareness, and continued industry participation, the market is expected to support broader protection against cervical cancer in the years ahead. 👉 Get detailed insights, revenue data, and growth forecasts in our latest market report. 📥 Download your sample research report now! #CervicalCancerVaccinesMarket #CervicalCancerPrevention #HPVVaccine #WomenHealth #PreventiveHealthcare #CancerVaccines #VaccineMarket #Immunization #PublicHealth #OncologyMarket #HealthcareInnovation #PharmaIndustry #BiotechMarket #WomensHealth #PersistenceMarketResearch

📢 New Article Spotlight in the VSI: Immunomodulatory Adjuvant of Materials Today Bio I am pleased to highlight the article: “Klebsiella pneumoniae vaccines: Evolving the blueprint from traditional platforms to mucosal and nanoscale delivery” This timely review addresses one of the most pressing global health challenges posed by Klebsiella pneumoniae (KP), particularly carbapenem-resistant and hypervirulent strains that continue to threaten healthcare systems worldwide amid the declining efficacy of antibiotics. Led by corresponding author Prof. Xin Li (李鑫) from Shandong First Medical University, this work provides a comprehensive and forward-looking overview of the evolving KP vaccine landscape — spanning traditional whole-cell and subunit vaccines to next-generation nanovaccine and mucosal immunization strategies. Particularly noteworthy is the article’s focus on: 🔹 Nanovaccine platforms, including OMVs and biosynthetic glycoconjugate nanoparticles 🔹 Mucosal vaccination strategies capable of blocking infection at the primary site of colonization 🔹 Translational opportunities for combating multidrug-resistant bacterial infections 🔹 Emerging immunomodulatory approaches for next-generation anti-infective therapeutics Prof. Li and colleagues have made significant contributions to novel vaccine development, pathogen–host interactions, and translational immunology through multidisciplinary innovation and advanced biomaterial engineering. This article offers valuable insights for researchers working in: #Vaccines #Nanomedicine #Biomaterials #Immunology #AntimicrobialResistance #DrugResistance #MucosalImmunity #NanoVaccines #InfectiousDiseases #Bioengineering #TranslationalMedicine #Microbiology #Immunotherapy #BiomedicalResearch #VaccineDevelopment I look forward to sharing more outstanding contributions from the special issue “Biomaterials as Next-generation Immunomodulatory Adjuvant” in the coming weeks.

#GetTheMessage The power of mRNA Medicines. Results published yesterday in the New England Journal of Medicine: Moderna's mRNA flu vaccine outperformed the standard flu shot by 27% in a Phase 3 trial. Fewer people got sick. Side effects were mild and short-lived. The data is clear. Here's why this matters beyond the numbers: Traditional flu vaccines take months to manufacture. Health officials have to guess which strains will circulate up to 12 months before flu season. When they guess wrong, effectiveness drops to 20-30%. mRNA changes that calculus. The platform is faster. Manufacturers can pivot if new strains emerge. Last summer, H3N2 subclade K appeared late in the season. A traditional vaccine couldn't adapt. An mRNA vaccine could. And yet. The FDA rejected Moderna's flu vaccine application earlier this year. HHS canceled nearly $500 million in mRNA research funding. And this week we learned that FDA officials directed scientists to withdraw COVID vaccine safety studies that had already been accepted for publication—studies that found serious side effects to be very rare. The efficacy data says mRNA works better. The safety data says mRNA is safe. HHS is blocking Americans from seeing both. Peter Hotez, Baylor College of Medicine: "We need to keep as many technologies in play as possible. To cut one of them out for ideological reasons limits our ability to protect the American people." Europe just approved Moderna's mRNA flu-COVID combination vaccine. Americans will have to wait—not because the science isn't ready, but because their own government won't let them see it. 🔗 https://lnkd.in/e7n58EeQ #mRNA #GetTheMessage #Vaccines #PublicHealth #AmericanInnovation Alliance for mRNA Medicines